

21. Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. *Vaccine*. 2011 Oct 26;29(46):8285–92. doi: <http://dx.doi.org/10.1016/j.vaccine.2011.08.108> PMID: 21907255
22. Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, Shin S, et al. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. *PLoS Negl Trop Dis*. 2014 Oct 6;8(2):e2629. doi: <http://dx.doi.org/10.1371/journal.pntd.0002629> PMID: 24516675
23. Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, Victor N, et al. Use of oral cholera vaccine in Haiti: a rural demonstration project. *Am J Trop Med Hyg*. 2013 Oct;89(4):617–24. doi: <http://dx.doi.org/10.4269/ajtmh.13-0183> PMID: 24106187
24. Rouzier V, Severe K, Juste MA, Peck M, Perodin C, Severe P, et al. Cholera vaccination in urban Haiti. *Am J Trop Med Hyg*. 2013 Oct;89(4):671–81. doi: <http://dx.doi.org/10.4269/ajtmh.13-0171> PMID: 24106194
25. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. Use of *Vibrio cholerae* vaccine in an outbreak in Guinea. *N Engl J Med*. 2014 May 29;370(22):2111–20. doi: <http://dx.doi.org/10.1056/NEJMoa1312680> PMID: 24869721
26. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. *PLoS Negl Trop Dis*. 2013 10 17;7(10):e2465. doi: <http://dx.doi.org/10.1371/journal.pntd.0002465> PMID: 24147164
27. Ciglenecki I, Sakoba K, Luquero FJ, Heile M, Itama C, Mengel M, et al. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. *PLoS Med*. 2013;10(9):e1001512. doi: <http://dx.doi.org/10.1371/journal.pmed.1001512> PMID: 24058301
28. Porta MI, Lenglet A, de Weerdts S, Crestani R, Sinke R, Frawley MJ, et al. Feasibility of a preventive mass vaccination campaign with two doses of oral cholera vaccine during a humanitarian emergency in South Sudan. *Trans R Soc Trop Med Hyg*. 2014 Dec;108(12):810–5. doi: <http://dx.doi.org/10.1093/trstmh/tru153> PMID: 25311798
29. Phares CR, Date K, Travers P, Déglise C, Wongjindanon N, Ortega L, et al. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand. *Vaccine*. 2016 Jan 2;34(1):128–33. doi: <http://dx.doi.org/10.1016/j.vaccine.2015.10.112> PMID: 26549363
30. Tohme RA, François J, Wannemuehler K, Iyengar P, Dismar A, Adrien P, et al. Oral cholera vaccine coverage, barriers to vaccination, and adverse events following vaccination, Haiti, 2013. *Emerg Infect Dis*. 2015 Jun;21(6):984–91. doi: <http://dx.doi.org/10.3201/eid2106.141797> PMID: 25988350
31. Oral cholera vaccine campaign among internally displaced persons in South Sudan. *Wkly Epidemiol Rec*. 2014 May 16;89(20):214–20. PMID: 24864347
32. Resolution WHA67.20. Regulatory system strengthening for medical products. In: Sixty-seventh World Health Assembly, Geneva, 19–24 May 2014. Resolutions and decisions, annexes. Geneva: World Health Organization; 2014 (WHA67/2014/REC/1). Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA67-REC1/A67_2014_REC1-en.pdf#page=1 [cited 2016 May 4].
33. Munira SL, Fritzen SA. What influences government adoption of vaccines in developing countries? A policy process analysis. *Soc Sci Med*. 2007 Oct;65(8):1751–64. doi: <http://dx.doi.org/10.1016/j.socscimed.2007.05.054> PMID: 17644230
34. Inactivated oral cholera [Internet]. Geneva: World Health Organization; 2011. Available from: http://www.who.int/immunization_standards/vaccine_quality/pq_250_cholera_1dose_shantha/en/ [cited 2017 Jan 15].
35. Saha A, Khan A, Salma U, Jahan N, Bhuiyan TR, Chowdhury F, et al. The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants. *Vaccine*. 2016 Mar 18;34(13):1551–8. doi: <http://dx.doi.org/10.1016/j.vaccine.2016.02.020> PMID: 26896684
36. Kanungo S, Desai SN, Nandy RK, Bhattacharya MK, Kim DR, Sinha A, et al. Flexibility of oral cholera vaccine dosing—a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone. *PLoS Negl Trop Dis*. 2015 03 12;9(3):e0003574. doi: <http://dx.doi.org/10.1371/journal.pntd.0003574> PMID: 25764513
37. Qadri F, Wierzbza TF, Ali M, Chowdhury F, Khan AI, Saha A, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. *N Engl J Med*. 2016 May 5;374(18):1723–32. doi: <http://dx.doi.org/10.1056/NEJMoa1510330> PMID: 27144848
38. Zambia: largest ever oral cholera vaccination campaign underway in Lusaka [Internet]. Geneva: Médecins Sans Frontières; 2016. Available from: <http://www.msf.org/en/article/zambia-largest-ever-oral-cholera-vaccination-campaign-underway-lusaka> [cited 2016 Apr 29].
39. Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, Lessler J. The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling study. *PLoS Med*. 2015 08 25;12(8):e1001867. doi: <http://dx.doi.org/10.1371/journal.pmed.1001867> PMID: 26305226
40. Stop cholera: frequently asked questions [Internet]. Baltimore: Johns Hopkins University; 2016. Available from: <https://www.stopcholera.org/content/frequently-asked-questions> [cited 2016 Aug 18].
41. Markwick AJ, Rennels MB, Zito ET, Wade MS, Mack ME; US Rhesus Rotavirus Vaccine Study Group. Oral tetravalent rotavirus vaccine can be successfully coadministered with oral poliovirus vaccine and a combined diphtheria, tetanus, pertussis and *Haemophilus influenzae* type b vaccine. *Pediatr Infect Dis J*. 1998 Oct;17(10):913–8. doi: <http://dx.doi.org/10.1097/00006454-199810000-00013> PMID: 9802635

Corrigendum

In Volume 95, Issue 3, March 2017, page 202, Table 3 should have an additional row:

Table 3. **Time delays in the receipt of doses of hepatitis B vaccine for children aged 12–60 months in 47 countries, by national hepatitis B vaccination schedule**

Vaccination schedule ^a and vaccine type	Country	First dose		Third dose	
		No. of children vaccinated	No. (%) with delayed vaccination	No. of children vaccinated	No. (%) with delayed vaccination
Pentavalent	Dominican Republic ^b	1 434	167 (12)	1 224	385 (31)

Schweitzer A, Akmatov MK, Krause G. Hepatitis B vaccination timing: results from demographic health surveys in 47 countries. *Bull World Health Organ*. 2017;95(3):202. doi: <http://dx.doi.org/10.2471/BLT.16.178822>